Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary (Q37313911)

19 August 2017

1 reference

title

Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary (English)

1 reference

19 August 2017

0 references

Rocio S Lopez-Diego

1

1 reference

PubMed ID

18974749

19 August 2017

Howard L Weiner

series ordinal

2

1 reference

19 August 2017

1 November 2008

1 reference

Nature Reviews Drug Discovery

19 August 2017

1 reference

19 August 2017

7

1 reference

19 August 2017

11

1 reference

19 August 2017

909-925

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd2358

19 August 2017

0 references

cites work

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

Defining the clinical course of multiple sclerosis: Results of an international survey

31 March 2020

1 reference

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

31 March 2020

1 reference

Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability

31 March 2020

1 reference

A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis

31 March 2020

1 reference

Axonal transection in the lesions of multiple sclerosis

31 March 2020

1 reference

Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation

31 March 2020

1 reference

Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time.

31 March 2020

1 reference

Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions.

31 March 2020

1 reference

Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis

31 March 2020

1 reference

In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis.

31 March 2020

1 reference

Short-term accrual of gray matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MRI.

31 March 2020

1 reference

Axonal injury and overall tissue loss are not related in primary progressive multiple sclerosis

31 March 2020

1 reference

31 March 2020

1 reference

Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system

31 March 2020

1 reference

Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease

31 March 2020

1 reference

Multiple sclerosis: a complicated picture of autoimmunity.

31 March 2020

1 reference

Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization

31 March 2020

1 reference

Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions

31 March 2020

1 reference

Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions

31 March 2020

1 reference

Tumor necrosis factor identified in multiple sclerosis brain

31 March 2020

1 reference

Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma

31 March 2020

1 reference

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

31 March 2020

1 reference

A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis

31 March 2020

1 reference

Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis.

31 March 2020

1 reference

Adhesion Molecules in Multiple Sclerosis

31 March 2020

1 reference

VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site.

31 March 2020

1 reference

Natalizumab effects on immune cell responses in multiple sclerosis

31 March 2020

1 reference

Differential effects of treatment with a small-molecule VLA-4 antagonist before and after onset of relapsing EAE.

31 March 2020

1 reference

Very late antigen 4-dependent adhesion and costimulation of resting human T cells by the bacterial beta 1 integrin ligand invasin

31 March 2020

1 reference

Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects

31 March 2020

1 reference

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

31 March 2020

1 reference

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

31 March 2020

1 reference

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

31 March 2020

1 reference

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

31 March 2020

1 reference

Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs

31 March 2020

1 reference

The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity

31 March 2020

1 reference

FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells.

31 March 2020

1 reference

Sphingosine-1-phosphate mediates migration of mature dendritic cells.

31 March 2020

1 reference

Sphingosine kinase and sphingosine-1-phosphate regulate migration, endocytosis and apoptosis of dendritic cells.

31 March 2020

1 reference

Antiproliferative properties of sphingosine-1-phosphate in human hepatic myofibroblasts

31 March 2020

1 reference

Sphingosine-1-phosphate is released by cerebellar astrocytes in response to bFGF and induces astrocyte proliferation through Gi-protein-coupled receptors.

31 March 2020

1 reference

Oral fingolimod (FTY720) for relapsing multiple sclerosis

31 March 2020

1 reference

Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction

31 March 2020

1 reference

Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood

31 March 2020

1 reference

Increased CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosis

31 March 2020

1 reference

Activated CD8+ T cells in secondary progressive MS secrete lymphotoxin

31 March 2020

1 reference

Cytokine producing CD8+ T cells are correlated to MRI features of tissue destruction in MS.

31 March 2020

1 reference

Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey

31 March 2020

1 reference

Immunotherapy of experimental autoimmune encephalomyelitis (EAE): Differential effect of anti-IL-2 receptor antibody therapy on actively induced and T-line mediated EAE of the Lewis rat

31 March 2020

1 reference

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

31 March 2020

1 reference

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

31 March 2020

1 reference

Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis

31 March 2020

1 reference

Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis.

31 March 2020

1 reference

Decreased FOXP3 levels in multiple sclerosis patients

31 March 2020

1 reference

Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+regulatory T-cell function and FOXP3 expression

31 March 2020

1 reference

Acute graft-vs-host disease: pathobiology and management

31 March 2020

1 reference

Prevention of lethal acute GVHD with an agonistic CD28 antibody and rapamycin

31 March 2020

1 reference

Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin

31 March 2020

1 reference

The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in mice.

31 March 2020

1 reference

Rapamycin enriches for CD4(+) CD25(+) CD27(+) Foxp3(+) regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis.

31 March 2020

1 reference

Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3

31 March 2020

1 reference

Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis

31 March 2020

1 reference

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

31 March 2020

1 reference

Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells

31 March 2020

1 reference

Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis

31 March 2020

1 reference

Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis

31 March 2020

1 reference

Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factorin situ

31 March 2020

1 reference

Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor

31 March 2020

1 reference

Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy

31 March 2020

1 reference

Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody

31 March 2020

1 reference

Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs

31 March 2020

1 reference

Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells.

31 March 2020

1 reference

Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis.

31 March 2020

1 reference

Histone peptide-induced nasal tolerance: suppression of murine lupus

31 March 2020

1 reference

The mechanism of nasal tolerance in lupus prone mice is T-cell anergy induced by immature B cells that lack B7 expression

31 March 2020

1 reference

Transforming growth factor beta induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis.

31 March 2020

1 reference

Sex differences in autoimmune disease

31 March 2020

1 reference

Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group.

31 March 2020

1 reference

Low-dose estrogen therapy ameliorates experimental autoimmune encephalomyelitis in two different inbred mouse strains

31 March 2020

1 reference

Estrogen treatment down-regulates TNF-alpha production and reduces the severity of experimental autoimmune encephalomyelitis in cytokine knockout mice.

31 March 2020

1 reference

Sex hormones in experimental autoimmune encephalomyelitis: implications for multiple sclerosis

31 March 2020

1 reference

Estrogen inhibition of EAE involves effects on dendritic cell function.

31 March 2020

1 reference

Cutting edge: estrogen drives expansion of the CD4+CD25+ regulatory T cell compartment

31 March 2020

1 reference

Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of Treg cells, and enhanced expression of the PD-1 costimulatory pathway

31 March 2020

1 reference

Treatment of multiple sclerosis with the pregnancy hormone estriol

31 March 2020

1 reference

Oral tolerance: therapeutic implications for autoimmune diseases

31 March 2020

1 reference

Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis.

31 March 2020

1 reference

Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity

31 March 2020

1 reference

Mucosal tolerance in a murine model of experimental autoimmune encephalomyelitis

31 March 2020

1 reference

Nasal administration of myelin basic protein prevents relapsing experimental autoimmune encephalomyelitis in DA rats by activating regulatory cells expressing IL-4 and TGF-beta mRNA.

31 March 2020

1 reference

Complexities of applying nasal tolerance induction as a therapy for ongoing relapsing experimental autoimmune encephalomyelitis (EAE) in DA rats

31 March 2020

1 reference

Inhibition of relapsing experimental autoimmune encephalomyelitis in SJL mice by feeding the immunodominant PLP139-151 peptide

31 March 2020

1 reference

T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis

31 March 2020

1 reference

Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein

31 March 2020

1 reference

Effective antigen-specific immunotherapy in the marmoset model of multiple sclerosis.

31 March 2020

1 reference

Myelin-specific tolerance attenuates the progression of a virus-induced demyelinating disease: implications for the treatment of MS.

31 March 2020

1 reference

Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes

31 March 2020

1 reference

31 March 2020

1 reference

Evolution of the T-cell repertoire during the course of experimental immune-mediated demyelinating diseases

31 March 2020

1 reference

Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial

31 March 2020

1 reference

Treatment of chronic relapsing experimental allergic encephalomyelitis with the intravenous administration of splenocytes coupled to encephalitogenic peptide 91-103 of myelin basic protein

31 March 2020

1 reference

An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis

31 March 2020

1 reference

Amelioration of relapsing experimental autoimmune encephalomyelitis with altered myelin basic protein peptides involves different cellular mechanisms

31 March 2020

1 reference

Therapeutic potential of TCR antagonists is determined by their ability to modulate a diverse repertoire of autoreactive T cells

31 March 2020

1 reference

NBI-5788, an altered MBP83-99 peptide, induces a T-helper 2-like immune response in multiple sclerosis patients

31 March 2020

1 reference

Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand

31 March 2020

1 reference

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune responsein multiple sclerosis after administration of an altered peptide ligand ina placebo-controlled, randomized phase II trial

31 March 2020

1 reference

An open trial of OKT3 in patients with multiple sclerosis

31 March 2020

1 reference

31 March 2020

1 reference

Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis

31 March 2020

1 reference

Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy

31 March 2020

1 reference

Nasal anti-CD3 antibody ameliorates lupus by inducing an IL-10-secreting CD4+ CD25- LAP+ regulatory T cell and is associated with down-regulation of IL-17+ CD4+ ICOS+ CXCR5+ follicular helper T cells

31 March 2020

1 reference

CD3-specific antibody-induced active tolerance: from bench to bedside

31 March 2020

1 reference

CD3-specific antibodies: a portal to the treatment of autoimmunity

31 March 2020

1 reference

Vaccination with DNA encoding an immunodominant myelin basic protein peptide targeted to Fc of immunoglobulin G suppresses experimental autoimmune encephalomyelitis

31 March 2020

1 reference

Protective DNA vaccination against organ-specific autoimmunity is highly specific and discriminates between single amino acid substitutions in the peptide autoantigen

31 March 2020

1 reference

Gene therapy in a murine model for clinical application to multiple sclerosis

31 March 2020

1 reference

A novel retroviral gene therapy approach to inhibit specific antibody production and suppress experimental autoimmune encephalomyelitis induced by MOG and MBP.

31 March 2020

1 reference

Cell-based gene therapy experiments in murine experimental autoimmune encephalomyelitis

31 March 2020

1 reference

Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway

31 March 2020

1 reference

Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis

31 March 2020

1 reference

Suppressive DNA vaccination in myelin oligodendrocyte glycoprotein peptide-induced experimental autoimmune encephalomyelitis involves a T1-biased immune response

31 March 2020

1 reference

A Suppressive Oligodeoxynucleotide Enhances the Efficacy of Myelin Cocktail/IL-4-Tolerizing DNA Vaccination and Treats Autoimmune Disease

31 March 2020

1 reference

Vaccination against autoimmune encephalomyelitis (EAE): Attenuated autoimmune T lymphocytes confer resistance to induction of active EAE but not to EAE mediated by the intact T lymphocyte line

31 March 2020

1 reference

Suppression of experimentally induced autoimmune encephalomyelitis by cytolytic T-T cell interactions.

31 March 2020

1 reference

T cell vaccination in multiple sclerosis: a preliminary report

31 March 2020

1 reference

MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination

31 March 2020

1 reference

Depletion of myelin-basic-protein autoreactive T cells by T-cell vaccination: pilot trial in multiple sclerosis

31 March 2020

1 reference

T cell vaccination in secondary progressive multiple sclerosis

31 March 2020

1 reference

Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis

31 March 2020

1 reference

Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides

31 March 2020

1 reference

Prevention and treatment of relapsing autoimmune encephalomyelitis with myelin peptide-coupled splenocytes

31 March 2020

1 reference

Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRV beta 6 CDR2 peptide.

31 March 2020

1 reference

Results of a phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell receptor utilization in CSF cell populations.

31 March 2020

1 reference

Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation.

31 March 2020

1 reference

A comparative analysis of B cell-mediated myelin oligodendrocyte glycoprotein-experimental autoimmune encephalomyelitis pathogenesis in B cell-deficient mice reveals an effect on demyelination

31 March 2020

1 reference

Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis.

31 March 2020

1 reference

Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis.

31 March 2020

1 reference

Unveiling the enigma of the CNS as a B-cell fostering environment

31 March 2020

1 reference

Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS.

31 March 2020

1 reference

Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis.

31 March 2020

1 reference

Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients

31 March 2020

1 reference

Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid.

31 March 2020

1 reference

Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis

31 March 2020

1 reference

Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein

31 March 2020

1 reference

BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma

31 March 2020

1 reference

Evidence for pathogenic heterogeneity in multiple sclerosis

31 March 2020

1 reference

Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange

31 March 2020

1 reference

Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients

31 March 2020

1 reference

Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab

31 March 2020

1 reference

Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis.

31 March 2020

1 reference

Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells.

31 March 2020

1 reference

Treatment of IgM antibody associated polyneuropathies using rituximab

31 March 2020

1 reference

An open label study of the effects of rituximab in neuromyelitis optica

31 March 2020

1 reference

Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis

31 March 2020

1 reference

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

31 March 2020

1 reference

Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H.

31 March 2020

1 reference

Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench

31 March 2020

1 reference

Optimal reference population for the multiple sclerosis functional composite

31 March 2020

1 reference

The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis

31 March 2020

1 reference

Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice

31 March 2020

1 reference

Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats

31 March 2020

1 reference

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

31 March 2020

1 reference

Development of cladribine treatment in multiple sclerosis

31 March 2020

1 reference

Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial

31 March 2020

1 reference

The new global multiple sclerosis severity score (MSSS) correlates with axonal but not glial biomarkers

31 March 2020

1 reference

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.

31 March 2020

1 reference

Mycophenolic acid inhibits inosine 5'-monophosphate dehydrogenase and suppresses immunoglobulin and cytokine production of B cells

31 March 2020

1 reference

Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells

31 March 2020

1 reference

Mycophenolate mofetil treatment accelerates recovery from experimental allergic encephalomyelitis.

31 March 2020

1 reference

Mycophenolate-mofetil in the treatment of refractory multiple sclerosis.

31 March 2020

1 reference

Mycophenolate mofetil in multiple sclerosis

31 March 2020

1 reference

Combination of IFN beta-1a (Avonex) and mycophenolate mofetil (Cellcept) in multiple sclerosis.

31 March 2020

1 reference

Oligodendrocyte NMDA receptors: a novel therapeutic target

31 March 2020

1 reference

Oxidative stress and the pathogenesis of neurodegenerative disorders

31 March 2020

1 reference

Human T cells express a functional ionotropic glutamate receptor GluR3, and glutamate by itself triggers integrin-mediated adhesion to laminin and fibronectin and chemotactic migration

31 March 2020

1 reference

Modulation of blood-brain barrier dysfunction and neurological deficits during acute experimental allergic encephalomyelitis by the N-methyl-D-aspartate receptor antagonist memantine

31 March 2020

1 reference

Autoimmune encephalomyelitis ameliorated by AMPA antagonists

31 March 2020

1 reference

Glutamate excitotoxicity in a model of multiple sclerosis

31 March 2020

1 reference

Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis

31 March 2020

1 reference

Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid

31 March 2020

1 reference

Glutamate uptake by oligodendrocytes: Implications for excitotoxicity in multiple sclerosis

31 March 2020

1 reference

Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis.

31 March 2020

1 reference

Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis

31 March 2020

1 reference

The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study

31 March 2020

1 reference

Glutamate inhibition in MS: the neuroprotective properties of riluzole

31 March 2020

1 reference

The promise of minocycline in neurology.

31 March 2020

1 reference

A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window

31 March 2020

1 reference

Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease

31 March 2020

1 reference

Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease

31 March 2020

1 reference

Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease.

31 March 2020

1 reference

Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice

31 March 2020

1 reference

Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice

31 March 2020

1 reference

Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury.

31 March 2020

1 reference

Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis

31 March 2020

1 reference

Inhibition of autoimmune encephalomyelitis by a tetracycline.

31 March 2020

1 reference

Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation

31 March 2020

1 reference

Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria

31 March 2020

1 reference

Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia

31 March 2020

1 reference

Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia.

31 March 2020

1 reference

The influence of tetracyclines on T cell activation

31 March 2020

1 reference

Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke

31 March 2020

1 reference

Additive effect of the combination of glatiramer acetate and minocycline in a model of MS.

31 March 2020

1 reference

Effective combination of minocycline and interferon-beta in a model of multiple sclerosis

31 March 2020

1 reference

Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis.

31 March 2020

1 reference

Benefit-risk assessment of acne therapies

31 March 2020

1 reference

Fetal and adult human oligodendrocyte progenitor cell isolates myelinate the congenitally dysmyelinated brain

31 March 2020

1 reference

Human embryonic stem cells differentiate into oligodendrocytes in high purity and myelinate after spinal cord transplantation

31 March 2020

1 reference

Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis.

31 March 2020

1 reference

Transplanted multipotential neural precursor cells migrate into the inflamed white matter in response to experimental autoimmune encephalomyelitis

31 March 2020

1 reference

Transplanted neural precursor cells reduce brain inflammation to attenuate chronic experimental autoimmune encephalomyelitis

31 March 2020

1 reference

Stem cell transplantation for autoimmune disorders. Preclinical experiments

31 March 2020

1 reference

Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores

31 March 2020

1 reference

Suppressing immunity in advancing MS: too much too late, or too late for much?

31 March 2020

1 reference

Autologous haematopoietic-stem-cell transplantation for multiple sclerosis

31 March 2020

1 reference

Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life

31 March 2020

1 reference

Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis.

31 March 2020

1 reference

Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: graft-versus-host disease and transplant-related mortality

31 March 2020

1 reference

Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis

31 March 2020

1 reference

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

31 March 2020

1 reference

Eight-year follow-up study of brain atrophy in patients with MS.

31 March 2020

1 reference

The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction.

31 March 2020

1 reference

Measurement of spinal cord atrophy in multiple sclerosis

31 March 2020

1 reference

Central nervous system atrophy and clinical status in multiple sclerosis

31 March 2020

1 reference

MR correlates of cerebral atrophy in patients with multiple sclerosis.

31 March 2020

1 reference

Measurement of brain and spinal cord atrophy by magnetic resonance imaging as a tool to monitor multiple sclerosis

31 March 2020

1 reference

Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand

31 March 2020

1 reference

Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy

31 March 2020

1 reference

Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients

31 March 2020

1 reference

CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions

31 March 2020

1 reference

Increased percentage of IL-12+ monocytes in the blood correlates with the presence of active MRI lesions in MS

31 March 2020

1 reference

Increased serum levels of interleukin-18 in patients with multiple sclerosis

31 March 2020

1 reference

IL-18 is linked to raised IFN-gamma in multiple sclerosis and is induced by activated CD4(+) T cells via CD40-CD40 ligand interactions

31 March 2020

1 reference

Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-gamma production of CD8+ T cells in secondary progressive multiple sclerosis

31 March 2020

1 reference

Dysregulation of IL-10 and IL-12p40 in secondary progressive multiple sclerosis

31 March 2020

1 reference

Altered maturation of circulating dendritic cells in primary progressive MS patients

31 March 2020

1 reference

Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response

31 March 2020

1 reference

The many roles of chemokines and chemokine receptors in inflammation

31 March 2020

1 reference

Cell surface adhesion molecules and cytokine profiles in primary progressive multiple sclerosis.

31 March 2020

1 reference

Immunopathogenesis of multiple sclerosis

31 March 2020

1 reference

Neuroprotection and repair by neurotrophic and gliotrophic factors in multiple sclerosis

31 March 2020

1 reference

Experimental models of neuroprotection relevant to multiple sclerosis

31 March 2020

1 reference

Pathogenesis of axonal and neuronal damage in multiple sclerosis

31 March 2020

1 reference

Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis

31 March 2020

1 reference

Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis

31 March 2020

1 reference

Development of biomarkers in multiple sclerosis

31 March 2020

1 reference

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

31 March 2020

1 reference

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

31 March 2020

1 reference

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

31 March 2020

1 reference

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

31 March 2020

1 reference

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

31 March 2020

1 reference

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

31 March 2020

1 reference

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

31 March 2020

1 reference

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

31 March 2020

1 reference

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

31 March 2020

1 reference

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

31 March 2020

1 reference

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

31 March 2020

1 reference

Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results

31 March 2020

1 reference

An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS

31 March 2020

1 reference

A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN

31 March 2020

1 reference

Mechanisms and current treatments of urogenital dysfunction in multiple sclerosis

31 March 2020

1 reference

Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment.

31 March 2020

1 reference

Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity

31 March 2020

1 reference

Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.

31 March 2020

1 reference

Combination therapy in multiple sclerosis.

31 March 2020

1 reference

Combination therapy for multiple sclerosis: the treatment strategy of the future?

31 March 2020

1 reference

31 March 2020

1 reference

Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study

31 March 2020

1 reference

Vitamin D and multiple sclerosis

31 March 2020

1 reference

Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases.

31 March 2020

1 reference

1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis

31 March 2020

1 reference

1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis

31 March 2020

1 reference

Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice

31 March 2020

1 reference

25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis

31 March 2020

1 reference

Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis

31 March 2020

1 reference

Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD2358

1 reference

19 August 2017

1 reference

PubMed ID

18974749